Skip to main content
. 2018 Nov 5;19:65–74. doi: 10.1016/j.molmet.2018.10.011

Figure 1.

Figure 1

Pharmacological inhibition of FAP improves glucose homeostasis without affecting plasma levels of insulin or glucagon. CPD60 was given by oral gavage and FAP and DPP-4 activity were measured in 16-week old male C57BL/6J mice. Then, the mice were placed on a HFD for 2–3 weeks and given the indicated doses of either CPD60 or vehicle (PBS) by oral gavage 30 min prior to each test. A) Plasma FAP activity following CPD60 treatment. B) Plasma DPP-4 activity following CPD60 treatment. C) Oral glucose tolerance test (OGTT) at various doses of CPD60 and area under curve analysis (AUC) (right). D) Intraperitoneal Glucose Tolerance Test (IPGTT) and AUC. E) Insulin levels during OGTT. F) Glucagon levels during OGTT. G) Insulin Tolerance Test (ITT) and AUC. H) Triglycerides (TGs) and AUC during a Lipid Tolerance Test (LTT). Results were analyzed using ANOVA (Panels C and D), Two-way ANOVA (Panels E and F) or two-tailed t-test (Panels G and H). *P < 0.05.